Hemophilia Treatment Market – Disease Type (Hemophilia A, Hemophilia B), Product (Recombinant Factor Concentrates), Patient (Pediatric, Adult), Treatment (Prophylaxis, On Demand), Therapy, Drug Class, Route of Administration, End-use – Global Forecast 2024 – 2032
Report ID: GMI2772
|
Published Date: July 2024
|
Report Format: PDF
Download free sample
Get a free sample of Hemophilia Treatment Market
Get a free sample of Hemophilia Treatment Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 12
Tables & Figures: 677
Countries covered: 22
Pages: 390
Download Free Sample
Hemophilia Treatment Market Size
Hemophilia Treatment Market size was valued at USD 13 billion in 2023 and is anticipated to witness growth at a CAGR of 5.6% between 2024 and 2032. Hemophilia treatment has enhanced significantly over the past few years, owing to the advent of novel products, thereby driving market growth.
Additionally, several government and non-government organizations are coming forth to promote awareness related to symptoms, diagnosis, and hemophilia treatment. For instance, the World Federation of Hemophilia (WFH) is actively operating to improve and sustain care for individuals with inherited bleeding disorders worldwide. Such initiatives increase the adoption of treatments, and aid in the overall market growth.
Further, the launch of novel therapies, such as extended half-life factor concentrates and non-factor replacement therapies, is broadening the therapeutic landscape. Collaborations between pharmaceutical companies and research institutions are accelerating the development of new treatment modalities, while favorable reimbursement policies in developed regions are making advanced treatments more accessible to patients, thereby simulating market growth.
Hemophilia treatment refers to the medical interventions used to manage and control bleeding in individuals with hemophilia, a genetic disorder that impairs the blood's ability to clot properly. The main goal of treatment is to replace the missing or deficient clotting factors in the blood to prevent or stop bleeding episodes.
Hemophilia Treatment Market Trends
Hemophilia Treatment Market Analysis
Based on disease type, the market is segmented as hemophilia A, hemophilia B, and other disease types. Hemophilia A disease segment dominated the market in 2023 accounting for USD 10.2 billion.
Based on product, the hemophilia treatment market is segmented into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, extended half-life products, desmopressin, antifibrinolytic agents, and gene therapy products. The recombinant coagulation factor concentrates segment is further divided into factor VIII and factor IX. The recombinant coagulation factor concentrates segment dominated the market in 2023 with a market share of 58.2%.
Based on patient, the hemophilia treatment market is segmented into pediatric and adult. The adult segment is further segmented into 19 to 44 and 45+ age group The adult segment is anticipated to grow at a CAR of 5.5% over the forecast years.
Based on treatment, the hemophilia treatment market is segmented into prophylaxis and on demand. The prophylaxis segment dominated the market in 2023 and is anticipated to reach USD 15.1 billion by 2032.
Based on therapy, the hemophilia treatment market is segmented into factor replacement therapy and non-factor replacement therapy. The factor replacement therapy segment dominated the market in 2023 and is anticipated to grow at a CAGR of 5.5% over the analysis timeframe.
Based on drug class, the hemophilia treatment market is categorized into vasopressin and coagulation factors. The coagulation factors segment held a market share of 94.7% in 2023.
Based on route of administration, the hemophilia treatment market is categorized into injectable, nasal spray, and oral. The injectable segment is anticipated to witness significant growth to reach USD 18.4 billion by 2023.
Based on end-use, the hemophilia treatment market is segmented into hospitals, clinics, hemophilia treatment centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to grow at a CAGR of 5.8% between 2024 - 2032.
North America hemophilia treatment market was valued at USD 5.8 billion in 2023 and is anticipated to reach USD 9.1 billion by 2032.
U.S. hemophilia treatment market is anticipated to grow at a CAGR of 5.1% between 2024 - 2032.
Germany is anticipated to witness robust growth in the global hemophilia treatment market.
Asia Pacific region will exhibit high growth over the forecast period.
Hemophilia Treatment Market Share
The competitive landscape in the market is characterized by a dynamic interplay among pharmaceutical companies striving to innovate therapies and enhance patient outcomes. Market competitiveness is driven by strategic alliances, acquisitions, and regulatory approvals aimed at expanding market reach and improving accessibility to advanced therapies globally. Key players such as Bayer AG, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited dominate with their comprehensive portfolios of clotting factor concentrates and novel therapies. These companies invest significantly in research and development to introduce extended half-life products and gene therapies that promise longer-lasting effects and potentially curative outcomes.
Hemophilia Treatment Market Companies
Prominent players operating in the hemophilia treatment industry include:
Hemophilia Treatment Industry News:
The hemophilia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Disease Type
Market, By Product
Market, By Patient
Market, By Treatment
By Therapy
By Drug Class
By Route of Administration
By End-use
The above information is provided for the following regions and countries: